HYFT

HYFT Stock Forecast & Price Target
HYFT Analyst Ratings
Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%
HYFT has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.
This aggregate rating is based on analysts' research of ImmunoPrecise Antibodies Ltd and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of ImmunoPrecise Antibodies Ltd and is not a guaranteed prediction by Public.com or investment advice.
HYFT Analyst Forecast & Price Prediction
Get the latest HYFT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in HYFT
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About ImmunoPrecise Antibodies Ltd (HYFT) Forecast
Analysts have given HYFT a Strong Buy based on their latest research and market trends.
According to 2 analysts, HYFT has a Strong Buy consensus rating as of Oct 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.
HYFT Analyst Forecast & Price Prediction
Get the latest HYFT stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in HYFT
Order type
Buy in
Order amount
Est. shares
0 shares
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.